Lexicon Pharmaceuticals, INC Form 4 insider transactions

Artal International S.C.A. converted 1,150,922 shares of Series A convertible preferred stock into 57,546,100 shares of Lexicon Pharmaceuticals common stock after satisfying certain conditions.

Director Judith L. Swain reports the acquisition of stock options and restricted stock units in Lexicon Pharmaceuticals.

Director Diane E. Sullivan reports the acquisition of stock options and restricted stock units in Lexicon Pharmaceuticals.

Christopher J. Sobecki, a director at Lexicon Pharmaceuticals, acquired stock options and restricted stock units on May 13, 2024.

Robert J. Lefkowitz, a director of Lexicon Pharmaceuticals, acquired stock options for 44,906 shares and 36,810 restricted stock units on May 13, 2024.

Raymond Debbane, a director of Lexicon Pharmaceuticals, acquired stock options and restricted stock units on May 13, 2024.

Director Samuel L. Barker reports acquisition of stock options and restricted stock units in Lexicon Pharmaceuticals.

Philippe Amouyal, a director at Lexicon Pharmaceuticals, acquired stock options and restricted stock units on May 13, 2024.

Judith L. Swain, a director at Lexicon Pharmaceuticals, executed stock options and disposed of 8,032 shares of common stock on April 28, 2024.

Director Christopher J. Sobecki reports the acquisition and disposal of Lexicon Pharmaceuticals common stock and restricted stock units on April 28, 2024.

Director Robert J. Lefkowitz reports changes in beneficial ownership of Lexicon Pharmaceuticals stock, including the disposition of shares related to restricted stock units.

Raymond Debbane, a director at Lexicon Pharmaceuticals, reports a transaction involving restricted stock units and common stock.

Director Samuel Barker reports acquisition and disposal of Lexicon Pharmaceuticals common stock and restricted stock units on April 28, 2024.

Director Philippe Amouyal reports the vesting of restricted stock units and subsequent ownership of Lexicon Pharmaceuticals common stock.

Artal International S.C.A. purchased 1,150,922 shares of Lexicon Pharmaceuticals Series A convertible preferred stock for $108.50 per share, totaling approximately $125 million.

Kristen Alexander, VP of Finance and Accounting at Lexicon Pharmaceuticals, reports the vesting and subsequent withholding of shares to cover tax obligations.

Lexicon Pharmaceuticals' CFO, Jeffrey Wade, reports the vesting and subsequent tax withholding of shares related to restricted stock units.

Wendy McDermott, VP of Human Resources at Lexicon Pharmaceuticals, reported the vesting and subsequent disposal of restricted stock units to cover tax obligations on February 28, 2024.

Alan J. Main, EVP of Innovation & Chemical Sciences at Lexicon Pharmaceuticals, reports the vesting and conversion of restricted stock units into common stock, along with a portion of shares withheld for tax obligations.

Kenneth B. Kassler-Taub, SVP of Regulatory & QA at Lexicon Pharmaceuticals, reported the vesting and subsequent disposal of restricted stock units to cover tax obligations on February 28, 2024.

Craig B. Granowitz, SVP and Chief Medical Officer of Lexicon Pharmaceuticals, reports the acquisition and disposition of common stock and restricted stock units on February 28, 2024.

Brian T. Crum, SVP, General Counsel & Secretary of Lexicon Pharmaceuticals, reports the vesting and subsequent sale of restricted stock units to cover tax obligations.

CEO Lonnel Coats reports the vesting and conversion of restricted stock units into common stock, along with a transaction to cover tax obligations.